Epstein-Barr virus latent membrane protein 2 peptide-MHC complex (EBV LMP2 pMHC)

The Epstein-Barr virus (EBV) latent membrane protein 2 (LMP2) peptide-MHC complex is a molecular target formed by the presentation of EBV-derived peptides on the surface of host cells via Major Histocompatibility Complex (MHC) class I molecules (UniProt P13285). LMP2 is a viral protein expressed during the latent phase of the EBV life cycle and is frequently found in EBV-associated malignancies such as nasopharyngeal carcinoma, Hodgkin lymphoma, and post-transplant lymphoproliferative disorders (Young & Rickinson, 2004, Nature Reviews Cancer). In these cells, the LMP2A isoform mimics B-cell receptor signaling to promote cell survival and maintain viral latency (Longnecker, 2000, Nature Reviews Immunology). Because these complexes are specific to EBV-infected cells, they serve as ideal targets for immunotherapy, particularly T-cell receptor (TCR)-engineered T cells and EBV-specific cytotoxic T lymphocytes (Prockop et al., 2020, Journal of Clinical Investigation). Recognition of the LMP2 peptide-MHC complex by a specific TCR triggers T-cell activation, leading to the targeted lysis of the tumor cell. Therapeutic development focuses on specific HLA restrictions, most commonly HLA-A*02:01 and HLA-A*11:01, to ensure precise targeting and minimize off-target effects (Lin et al., 2018, Frontiers in Immunology).

Other names

EBV LMP2-HLA complexLMP2 peptide-HLA complexLatent membrane protein 2-MHC complexLMP2A peptide-MHCLMP2B peptide-MHC

Recognition by T-cell receptors (TCRs) on CD8+ cytotoxic T lymphocytes (CTLs) leading to T-cell activation, secretion of perforins and granzymes, and subsequent lysis of EBV-infected cells (Prockop et al., 2020, Journal of Clinical Investigation).